Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, and APT Medical [2][4][29] - The report also maintains an "Outperform" rating for H-Shares including Hansoh Pharmaceutical Group, 3SBio, PATEO, Akeso, and related targets such as Innovent Biologics and WuXi AppTec (H-Shares) [2][7][29] Core Insights - The report continues to recommend the innovative drug and device industry chain [1][2] - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW Pharma Bio index falling by 3.6% compared to a 1.7% drop in the SHCOMP [2][10] - The premium of the pharmaceutical sector to all A-Shares is currently at a normal level of 72.6% as of the end of November 2025 [17][22] Summary by Sections A-Shares Performance - The report highlights the A-Shares that are recommended for investment, maintaining an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine and Sichuan Kelun Pharmaceutical, among others [4][5] - The report notes that the pharmaceutical sector's performance was ranked 23rd among Shenwan's first-level industries in November 2025 [10][12] H-Shares Performance - The report indicates that the H-Shares pharmaceutical sector performed in line with the market, with the Hang Seng Healthcare index down by 0.1% and the biotech sector up by 0.4% in November 2025 [2][23] - Top gainers in the H-Shares market included Laekna, Inc. (+40%) and Clover Biopharmaceuticals, Ltd. (+22%) [23] U.S. Market Performance - The U.S. pharmaceutical sector outperformed the broader market in November 2025, with the S&P Healthcare Select Sector rising by 9.1% compared to a 0.1% increase in the S&P 500 [23]

Summary of Conference Call on ADC Industry Industry Overview - The A-share and H-share pharmaceutical sectors experienced a pullback after September 10, 2025, currently in a state of fluctuation, but confidence in domestic innovative drugs remains strong, with low-expectation BD projects gaining renewed attention, significantly boosting company stock prices [1][4][5] - Global BD and M&A activities increased significantly in 2025, reflecting the demand for new pipelines from large pharmaceutical companies, with Chinese enterprises playing a crucial role in global BD activities, indicating a trend towards consolidation in the pharmaceutical industry [1][5] Core Insights on ADC Technology - ADC technology has evolved through several generations, with domestic companies showing clear advantages in optimizing ADCs through engineering methods to improve antibodies, linkers, and toxins, potentially replacing traditional chemotherapy and enhancing treatment efficacy [1][7] - In 2026, a large number of key clinical trial data for ADCs combined with bispecific antibodies are expected to be released, with new targets, toxins, and drug forms driving industry development and providing positive catalysts for the market [1][8] Clinical Data and Market Performance - In 2025, significant clinical data was released in the ADC industry, enhancing market confidence, particularly with the XBI index showing strong performance post-September, reflecting high market interest in innovative drugs [3] - ADCs demonstrated significant survival benefits in first-line treatments, with long-term OS data showing promising results, indicating that more first-line treatments may be led by ADCs in the future [2][13] Safety and Efficacy Challenges - While ADCs show superior efficacy compared to traditional chemotherapy, they still face safety challenges, such as the risk of infections or ocular toxicity from MNAE products, making the management of side effects by physicians crucial [9][10] - The importance of managing side effects is emphasized, as adverse reactions typically do not threaten patient life, and better management strategies are expected to evolve with increased clinical application [10][11] Key Considerations for ADC Platforms - When selecting ADC platforms, it is essential to focus on early clinical data and the controllability of safety issues, as historical data indicates strong continuity in clinical outcomes from phase I to phase II trials [12] Future Trends and Catalysts - Looking ahead to 2026 and beyond, two main trends are anticipated: the rapid support of more positive data for large indication first-line treatments and the emergence of more data on ADCs used in combination with other drugs [14] - New ADCs targeting novel mechanisms and indications are expected to emerge, with companies exploring combinations of therapies for autoimmune diseases and addressing resistance in hard-to-treat targets [15][17] Promising Companies in ADC Development - Notable ADC development companies include Kelun-Biotech, BaiLi Tianheng, and YingEn, with promising products like Kelun-Biotech's CHOP2 ADC and BaiLi Tianheng's bispecific ADC showing strong performance [18] - Pfizer's ADC products, particularly those utilizing MMAE technology, are still considered valuable despite recent trends favoring other approaches, indicating ongoing potential in their efficacy against certain epithelial tumors [18]

Consumer Macro Strategy - The overall performance of the discretionary consumption sector is flat as the year-end approaches, but high-end consumption, including duty-free shopping in islands, is expected to gradually stabilize overall consumption [2][10] - The implementation plan released on November 26 aims to enhance the adaptability of supply and demand for consumer goods, with a goal to optimize the supply structure by 2027, creating three trillion-yuan consumption fields and ten hundred-billion-yuan consumption hotspots [2][10] - By 2030, a high-quality development pattern of mutual promotion between supply and consumption is expected to be established, with consumption steadily contributing to economic growth [2][10] New Consumption Manufacturing - The pet economy continues to thrive, with companies like Guobao Pet investing in high-end pet food factories in New Zealand, enhancing competitiveness in international markets [23][24] - The AI and 3D printing sector is rapidly evolving, with significant advancements expected in consumer-grade 3D printing by 2026, driven by companies like Huina Technology and Snapmaker [25][26] - The integration of AI with 3D printing is being promoted in educational settings, expanding the supply space for the industry [25] Light Industry Manufacturing - The home appliance sector is facing weak domestic demand, but there are opportunities for companies with overseas production capabilities and brand advantages as demand recovers [26][27] - The new tobacco sector is experiencing growth, particularly in e-cigarette exports to the U.S., which saw a significant increase in October [27][28] - The packaging industry is showing signs of profitability improvement despite a slight decline in revenue, driven by leading companies capturing market share from smaller firms [28] Textile and Apparel - The apparel sector is experiencing fluctuations in consumer demand, with a focus on companies that can demonstrate unique advantages in the market [30][31] - The export market remains under pressure due to trade tensions, but leading textile manufacturers are expected to present investment opportunities as they maintain strong positions in the industry [31] Beauty and Personal Care - The beauty sector shows positive fundamentals, with a 9.6% year-on-year increase in retail sales for cosmetics in October, although valuations have been affected by the new consumption sector [32][33] - The medical beauty segment is expanding, with new products gaining regulatory approval, indicating growth potential in the market [33] Home Appliances - Focus on two directions: resilient white goods leaders with strong cash flow and black goods leaders benefiting from optimized domestic sales and stable costs [34][35] - The white goods sector is facing pressure in domestic sales, while black goods are seeing improvements in average prices and export recovery [36][37]

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the first nine months of 2025 [1]. Industry Summary - In September 2025, the production of chemical pharmaceutical raw materials in China was 295,000 tons, representing a year-on-year decrease of 3.6% [1]. - Cumulatively, from January to September 2025, the total production of chemical pharmaceutical raw materials reached 2.721 million tons, showing a cumulative growth of 1.2% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the chemical pharmaceutical sector include Heng Rui Medicine (600276), East China Pharmaceutical (000963), Lizhu Group (000513), Baiyunshan (600332), North China Pharmaceutical (600812), Haizheng Pharmaceutical (600267), Fosun Pharmaceutical (600196), Kelun Pharmaceutical (002422), Enhua Pharmaceutical (002262), and Xianju Pharmaceutical (002332) [1].

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].

Global Market Dynamics - European stock indices showed slight increases, with Germany's DAX up by 0.18%, and the UK's FTSE 100 and France's CAC 40 rising by 0.02% and 0.04% respectively [2] - Commodity prices for copper, aluminum, and zinc declined, while nickel and tin experienced slight recoveries [2] - The ongoing Russia-Ukraine conflict remains tense, with Putin stating that negotiations hold no substantial meaning, while Zelensky is focused on implementing security agreements [2] Market Behavior Analysis - The concepts of "oscillating accumulation" and "phased reduction" are highlighted, where both can create false breakout signals but serve different purposes: the former is for future positioning, while the latter is for profit-taking [5] - Traditional analysis methods often rely on subjective judgment, making investment decisions feel uncertain; in contrast, quantitative methods provide clearer insights by focusing on institutional trading behaviors [5] Quantitative Data Insights - A data system can effectively display trading behaviors, with specific indicators showing the level of institutional activity; for instance, "institutional inventory" data indicates the involvement of institutional investors [8] - Examples of Huadong Medicine and Zhenzhou Cell illustrate how quantitative data can differentiate between institutional-led movements and short-term trading activities, leading to divergent market outcomes [8] Retail Investor Challenges - Retail investors face a barrage of information, including potential Fed interest rate cuts and OPEC+ production assessments, highlighting the need for improved interpretative skills rather than just information acquisition [9] - The importance of institutional participation in market movements is emphasized, suggesting that trends without significant institutional backing are likely to be short-lived [10] Recommendations for Investors - Investors are advised to shift focus from price to trading behavior, recognize institutional footprints, avoid emotional trading, and utilize tools that clearly display capital flows [12]

Investment Rating - The report does not explicitly state an investment rating for the GLP-1RA drug industry Core Insights - The GLP-1 receptor agonists (GLP-1RA) are a class of drugs that mimic the action of GLP-1, promoting insulin secretion and reducing appetite, leading to blood sugar control and weight loss [2][3] - The global market for GLP-1 drugs is dominated by semaglutide and tirzepatide, with semaglutide achieving sales of $16.6 billion in the first half of 2025, making it the top-selling drug globally [8] - The expiration of patents for major drugs is expected to lead to a surge in generic versions, increasing market competition and reducing treatment costs [11] Summary by Sections GLP-1 Drug Classification and Mechanism - GLP-1RA drugs are categorized into short-acting, long-acting, and ultra-long-acting formulations, each with different pharmacokinetic profiles [2][3] - These drugs are effective in treating conditions such as obesity, type 2 diabetes, and metabolic disorders [4] Market Performance and Patent Expiration - The sales of GLP-1 drugs have shown significant growth, with semaglutide's weight management product Wegovy achieving $5.441 billion in sales, a 78% increase year-over-year [8] - Key patents for drugs like liraglutide have expired, while others like semaglutide will expire in 2026, paving the way for biosimilars [9][11] R&D Progress in China - Chinese companies are advancing in the development of dual-target and multi-target GLP-1 drugs, with significant progress in clinical trials [13][14] - The focus is shifting towards expanding indications for GLP-1 drugs beyond diabetes and obesity to include conditions like Alzheimer's and cardiovascular diseases [15] Future Market Potential - The Chinese GLP-1 market is projected to grow from 9.62 billion yuan in 2020 to 71.7 billion yuan by 2029, with a compound annual growth rate (CAGR) of 22.1% [22] - The inclusion of GLP-1 drugs in national health insurance is expected to enhance market penetration and accessibility [22] Innovation Trends - The industry is witnessing a trend towards multi-target drug development and the introduction of oral formulations to improve patient compliance [28][29] - The competitive landscape is intensifying as both original and generic drug manufacturers seek to establish a foothold in the market [30][31]

Group 1 - The hepatitis concept sector declined by 0.31%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the hepatitis sector that saw significant outflows include Zhongsheng Pharmaceutical with a net outflow of 684 million yuan, followed by Te Yi Pharmaceutical and Pian Zai Huang with net outflows of 112 million yuan and 81 million yuan respectively [2][3] - Conversely, stocks that experienced net inflows include Baihua Pharmaceutical, Huadong Medicine, and Kangzhi Pharmaceutical, with inflows of 97.75 million yuan, 43.11 million yuan, and 21.20 million yuan respectively [6] Group 2 - The top gainers in the hepatitis sector included Baihua Pharmaceutical, which rose by 10.01%, followed by Chengda Pharmaceutical and Kangzhi Pharmaceutical with increases of 4.79% and 3.00% respectively [1][6] - The overall market sentiment for the hepatitis sector appears negative, as evidenced by the significant net outflows and the number of stocks declining in value [2][3] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78%, indicating active trading despite the price drop [2][3]

Market Overview - The chemical pharmaceutical sector increased by 0.02% on November 28, with Yifang Bio leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Top Gainers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 29.48, up 5.93% with a trading volume of 206,700 shares and a transaction value of 590 million [1] - Bibet (688759) closed at 34.88, up 5.47% with a trading volume of 115,300 shares [1] - Weier Pharmaceutical (603351) closed at 28.83, up 5.45% with a trading volume of 19,400 shares and a transaction value of 54.88 million [1] - Other notable gainers include Tingjian (002653) up 4.43% and Dongcheng Pharmaceutical (002675) up 3.53% [1] Top Losers in Chemical Pharmaceutical Sector - Guangji Pharmaceutical (000952) saw a significant decline of 9.98%, closing at 9.38 with a trading volume of 1,153,700 shares [2] - New Ganjing (920367) decreased by 5.73%, closing at 21.57 with a trading volume of 37,700 shares [2] - Hendi Pharmaceutical (301211) fell by 5.24%, closing at 15.19 with a trading volume of 310,700 shares [2] - Other notable losers include Beida Pharmaceutical (000788) down 3.80% and Fuyuan Pharmaceutical (6801089) down 3.71% [2] Fund Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 599 million from institutional investors, while retail investors saw a net inflow of 377 million [2] - Notable net inflows from retail investors were observed in stocks like Yifang Bio and Bibet, despite overall net outflows from institutional and speculative funds [3] Individual Stock Fund Flow - Yifang Bio had a net inflow of 57.86 million from institutional investors, but a net outflow from speculative and retail investors [3] - Huadong Pharmaceutical (000963) also saw a significant net inflow of 56.40 million from institutional investors, with outflows from speculative and retail investors [3] - Other stocks like Bibet and Dongcheng Pharmaceutical showed mixed fund flows, indicating varied investor sentiment [3]

Summary of Key Points from China Healthcare Conference and Tour Industry Overview - **Industry**: China Healthcare - **Focus**: Innovation, Globalization, and Recovery in Medical Technology (Medtech) Core Insights 1. **Innovation Hub**: China is establishing itself as a global innovation hub, particularly in novel modalities such as IO bispecific, ADC, and siRNA [1][2] 2. **Medtech Globalization**: Leading Chinese medical equipment companies are moving beyond simple exports to establish localized production and direct sales networks [1][3] 3. **IVD Market Recovery**: The domestic In-Vitro Diagnostics (IVD) market is showing signs of bottoming out, with hospitals incentivized to switch to cost-effective domestic solutions due to pricing pressures [1][4] 4. **CXO Sector Performance**: Strong orders in the CXO sector are sustained, with potential price recovery in domestic clinical CROs expected to improve gross margins in 2026 [1][5] Company-Specific Highlights 1. **Abbisko (2256.HK)** - Focus on clinical progress of irpagratinib and ABSK043, with a strong pipeline that remains undervalued in the market [15] - Irpagratinib's Phase 3 study for HCC is on track, and ABSK043 shows promise in combination therapies [16][17] 2. **Huadong Medicine (000963.SZ)** - Innovative drugs contributed Rmb1,675 million in sales for 9M25, up 62% YoY, with a focus on oncology and metabolic diseases [19] - Ongoing discussions for potential out-licensing of GLP-1 candidates and ADC [20] 3. **MicroPort MedBot (2252.HK)** - YTD overseas orders exceeded 70, indicating rapid commercialization in international markets [23] - Targeting cash flow breakeven in 2026, with a focus on increasing revenue from high-margin consumables [24][25] 4. **Shanghai Fosun Pharma (2196.HK)** - Optimistic about the inclusion of CAR-T therapy Yescarta in the innovative drug catalog of commercial insurance, expected to accelerate coverage [28] - Increasing R&D investment by 20% YoY, focusing on new modalities like radiopharmaceuticals [30] 5. **Henlius (2696.HK)** - HLX43 shows promising data in NSCLC, with plans for multiple registrational trials [31][33] - Developing a new platform for radiopharmaceuticals and small nucleic acids [32] 6. **Shenzhen Mindray (300760.SZ)** - Aiming to double its current 10% market share in IVD within three years, leveraging comprehensive lab solutions [37] - Global strategy focuses on localization and diversification of manufacturing [38] 7. **Tigermed (3347.HK)** - Positive revenue growth guidance for 2025, with strong orders in Phase 1/2 trials [40][42] - Expanding overseas operations, with significant growth in the US and Japan [43] 8. **United Imaging (688271.SS)** - Achieving robust growth in developed markets, with a CAGR of 50% for overseas markets expected [44][48] - Strong positioning in high-end MRI and molecular imaging sectors [47] Additional Insights - **siRNA Modality**: The siRNA field is at an inflection point, attracting significant interest from multinational corporations due to its long-dosing interval potential [2][9] - **Market Dynamics**: The domestic IVD market is experiencing a structural shift favoring domestic leaders, with hospitals seeking cost-effective solutions [4][14] - **Globalization Trends**: Chinese medtech firms are successfully executing globalization strategies, with significant growth in emerging markets [3][13] This summary encapsulates the key takeaways from the China Healthcare Conference and Tour, highlighting the industry's focus on innovation, globalization, and recovery, along with specific insights into leading companies within the sector.